 |
|
GEN reports on strategies to overcome blood-brain barrier
February 06, 2009The blood-brain barrier (BBB) remains a major obstacle to the successful delivery of drugs to treat central nervous system (CNS) disorders, reports Genetic Engineering and Biotechnology News (GEN). Researchers are exploring a variety of approaches to preserve the ability of the BBB to block harmful and toxic substances from entering the brain and to permit the passage of effective medicines for the treatment of CNS diseases, according to the February 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2778).
"The blood-brain barrier issue probably serves as the most significant roadblock to the treatment of central nervous system diseases," says John Sterling, Editor in Chief of GEN. "The key challenge is to treat people suffering from CNS disorders while trying to stay true to the physician's oath, 'First do no harm'."
One technology for enabling active transport of small molecule drugs across the BBB involves targeting endogenous nutrient transporters. These transporters are members of the solute carrier (SLC) transporter superfamily. Transport of small molecules across the BBB by these membrane proteins is known as carrier-mediated transport (CMT).
In order to design drugs that utilize CMT to cross the BBB, researchers modify their chemical structures so that they resemble nutrients that are transported across the BBB by specific SLCs. The prototypical drug that uses this strategy (which was developed long before mechanisms of CMT were known) is L-DOPA, the major current drug for Parkinson's disease. L-DOPA is used to replace dopamine that is lost due to degeneration of dopaminergic neurons in the substantia nigra of the brain.
Another major system that is used in normal mammalian physiology to enable needed molecules to cross the BBB is receptor-mediated transport (RMT). The brain uses RMT to transport proteins, peptides, and lipoproteins that are needed for brain function across the BBB. Examples of biomolecules that are transported into the brain via RMT include insulin, insulin-like growth factor (IGF), leptin, transferrin, and low-density lipoprotein (LDL).
In RMT, molecules in the circulation may bind to specific receptors on the luminal surface of brain capillaries (i.e., the surface that interfaces with the bloodstream). Upon binding, the receptor-ligand complex is internalized into the endothelial cell by a process called receptor-mediated endocytosis. The ligand may then be transported across the abluminal membrane of the endothelial cell (i.e., the membrane that interfaces with brain tissue) into the brain. This whole process is called receptor-mediated transcytosis.
Mary Ann Liebert, Inc./Genetic Engineering News
In order to design drugs that utilize CMT to cross the BBB, researchers modify their chemical structures so that they resemble nutrients that are transported across the BBB by specific SLCs. The prototypical drug that uses this strategy (which was developed long before mechanisms of CMT were known) is L-DOPA, the major current drug for Parkinson's disease. L-DOPA is used to replace dopamine that is lost due to degeneration of dopaminergic neurons in the substantia nigra of the brain.
Another major system that is used in normal mammalian physiology to enable needed molecules to cross the BBB is receptor-mediated transport (RMT). The brain uses RMT to transport proteins, peptides, and lipoproteins that are needed for brain function across the BBB. Examples of biomolecules that are transported into the brain via RMT include insulin, insulin-like growth factor (IGF), leptin, transferrin, and low-density lipoprotein (LDL).
In RMT, molecules in the circulation may bind to specific receptors on the luminal surface of brain capillaries (i.e., the surface that interfaces with the bloodstream). Upon binding, the receptor-ligand complex is internalized into the endothelial cell by a process called receptor-mediated endocytosis. The ligand may then be transported across the abluminal membrane of the endothelial cell (i.e., the membrane that interfaces with brain tissue) into the brain. This whole process is called receptor-mediated transcytosis.
Mary Ann Liebert, Inc./Genetic Engineering News
Blood-brain Barrier Current Events and Blood-brain Barrier News RSSShifting cellular energy metabolism may help treat cardiovascular disease
Drugs that target the way cells convert nutrients into energy could offer new approaches to treating a range of conditions including heart attack and stroke.
Inhibiting serotonin in gut could cure osteoporosis
An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in the Feb. 7 issue of Nature Medicine.
Promising new neuroimaging techniques for early detection of Alzheimer's disease
Investigators from the International Center for Biomedicine and the University of Chile, in collaboration with the Center for Bioinformatics of the Universidad de Talca, have discovered that two drugs, the benzimidazole derivatives lanzoprazole and astemizole, may be suitable for use as PET (positron emission tomography) radiotracers and enable imaging for the early detection of Alzheimer's Disease.
New class of brain-protecting drugs emerging
Researchers have identified a compound that mimics one of the brain's own growth factors and can protect brain cells against damage in several animal models of neurological disease.
Common heart medications may also protect against Parkinson's disease, study finds
UCLA researchers have discovered that a specific type of medication used to treat cardiovascular conditions such as hypertension, angina and abnormal heart rhythms may also decrease the risk of developing Parkinson's disease.
Compounds that help protect nerve cells discovered by Duke team
Scientists at Duke University Medical Center have found some compounds that improve a cell's ability to properly "fold" proteins and could lead to promising drugs for degenerative nerve diseases, including Huntington's disease, Alzheimer's disease and Parkinson's disease.
Experimental drug shows promise against brain, prostate cancers
An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.
UR Study Reveals Chemo's Toxicity to Brain, Possible Treatment
Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.
Scripps research scientists find new link between insulin and core body temperature
A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature.
Scientists successfully reprogram blood cells
Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.
More Blood-brain Barrier Current Events and Blood-brain Barrier News Articles
 |
The Blood Brain Barrier by Tomas R. Helio (Editor) The blood-brain barrier (BBB) is a membranic structure that acts primarily to protect the brain from chemicals in the blood, while still allowing essential metabolic function. It is composed of endothelial cells, which are packed very tightly in brain capillaries. This higher density restricts passage of substances from the bloodstream much more than endothelial cells in capillaries elsewhere in the body. Astrocyte cell projections called astrocytic feet (also known as 'glia limitans') surround the endothelial cells of the BBB, providing biochemical support to those cells. The BBB is distinct from the similar blood-cerebrospinal fluid barrier, a function of the choroidal cells of the choroid plexus, and from the Blood-retinal barrier, which can be considered a part of the whole (the... |
 |
Blood Brain Barrier Jason Short (Primary Contributor) |
 |
Blood Brain Barrier by Aube |
 |
Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology by William M. Pardridge MD (Editor) Knowledge of the blood-brain barrier forms an essential component in the understanding of a large proportion of medical disciplines. Nevertheless, ignorance in this field still impedes progress in many areas, including cerebrovascular disease, Alzheimer's disease, cerebral AIDS, brain tumors, and the development of effective new neuropharmaceuticals. This introduction for both researchers and clinicians across the medical sciences is intended to aid both those beginning work directly in this area and those wishing simply to be better informed when interpreting information where the blood-brain barrier may be involved. Recent advances in both methodology and biology are detailed in fifty state-of-the-art chapters written by international authorities. |
 |
Relaxity-Live Calm 10 CT Relaxity by Relaxity Relaxity is a natural, whole food based supplement that is made with a proprietary blend of gamma-aminobutyric acid (GABA, naturally produced) combined with ancient adaptogenic herbs. Relaxitys GABA has been proven through double-blind placebo controlled clinical tests on humans to increase Alpha brain waves and decrease Beta brain waves which creates a non-drowsy sense of relaxation and calmness while maintaining mental focus.* GABA is an inhibitory neurotransmittor that is naturally occurring in the brain of humans. The body does not produce enough GABA to overcome the stressful forces that are inherent in todays lifestyle, therefore it is beneficial to supplement to overcome this imbalance. Unlike other artificially synthesized forms of GABA, Relaxitys GABA is produced through an all... |
 |
The Blood-Brain Barrier and Its Microenvironment: Basic Physiology to Neurological Disease by Elga de Vries (Editor), Alexandre Prat (Editor) This reference analyzes the cellular and molecular biology and mechanisms of the blood-brain barrier (BBB) and presents the most recent studies on the role of the BBB in the development and initiation of a wide range of physiological and pathological conditions affecting the central nervous system. |
 |
Bonaparte Crossing the Blood-Brain Barrier Alec K. Redfearn And The Eyesores (Primary Contributor) |
 |
The Blood-Brain Barrier and Drug Delivery to the CNS by Michael Bradbury (Editor), David Begley (Editor), Jorg Kreuter (Editor) King's College, London, UK. Addresses how to determine drug permeability across the blood-brain barrier more effectively. Focuses on physiological mechanisms influencing the passage of agents into the brain and covers the latest research, problems and solutions, existing strategies, and prospects for future research. For researchers. Expanded-outline format. |
 |
Bonaparte Crossing the Blood - Brain Barrier Alec K. Redfearn And The Eyesores (Primary Contributor) |
 |
Blood Brain Barrier: Drug Delivery and Brain Pathology by David Kobiler (Editor), Shlomo Lustig (Editor), Shlomo Shapira (Editor) These proceedings review and discuss the different aspects of the biology of the Blood-Brain Barrier (BBB) and its involvement in the pathogenesis of brain disorders. The BBB, formed by a complex cellular system of endothelial cells, astroglia, pericytes, perivascular macrophages and a basal membrane, serves as a controlled functional gate to CNS. In vitro and in vivo models have been established to study the cellular and molecular interaction within the BBB and between the BBB and the neural cells. The structural and functional integrity of the BBB was shown to be dramatically altered during various diseases of the CNS, including neoplasia, ischemia, trauma, inflammation and bacterial and viral infections. Two approaches to drug delivery across the BBB have been pursued, ... |
| © 2010 BrightSurf.com |